RESUMEN
Aim To investigate whether low dose gem- citabine ( GEM) could enhance the anti-pancreatic cancer effects of human umbilical vein endothelial cell (HUVEC) vaccine.Methods C57BL/6 mice were randomly divided into four groups; PBS control group, GEM group, HUVEC vaccine group and HUVEC vaccine combined GEM group ( HUVEC-GEM group).Mice were inoculated with Pan02 pancreatic cancer cells to establish a subcutaneous xenograft model to observe tumor growth and adverse reactions in tumor bearing mice.Whether GEM could enhance the immune responses induced by HUVEC vaccine was determined by ELISA analysis of the immune serum, splenic lymphocyte proliferation assay, cytotoxic T lymphocyte killing assay and IFN-7 content assay.Results The results of subcutaneous transplantation tumor model showed that the introduction of GEM into the HU-VEC vaccine treatment could enhance the therapeutic anti-pancreatic cancer effects of HUVEC vaccine.Enzyme-linked immunoassay results confirmed that GEM acted as an immune adjuvant could effectively increase the HUVEC antibodies and I FN-7 level in the immune serum of mice.The results of lymphocyte proliferation experiment and CTL killing activity assay indicated that GEM could effectively enhance the spleen lymphocyte transformation activity and CTL killing ability of HUVEC vaccine immunized mice.Conclusions Low dose GEM could enhance the immune responses induced by HUVEC vaccine and thus enhance the anti- Pan02 pancreatic cancer effects of HUVEC vaccine.
RESUMEN
Aim To investigate the anti-EAC breast cancer effects of viable human umbilical vein endothe-lial cells ( HUVECs) vaccine. Methods Subconflu-ent HUVECs were mixed with OK432 to prepare HU-VECs-OK432 vaccine, and the anti-tumor efficacy of HUVECs-OK432 was investigated using a subcutaneous tumor model of EAC breast cancer. ELISA, splenic lymphocyte proliferation assay and cytotoxic T lympho-cytes ( CTL ) killing assay were adopted to detect the humoral and cellular immune responses after HUVECs-OK432 immunization. Results HUVECs-OK432 im-munization significantly inhibited the growth of EAC tumor in mice in the prophylactic procedures. High ti-ter of anti-HUVEC antibody was elicited by HUVECs-OK432 immunization. The proliferation activity of splenocytes from mice immunized with HUVECs-OK432 was significantly increased. T lymphocytes iso-lated from HUVECs-OK432-immunized mice were dose dependently killing HUVECs in vitro. Conclusion Strong humoral and cellular immune responses targeting HUVEC are elicited by HUVECs-OK432 immuniza-tion, which results in a significant inhibition on the growth of EAC tumor in mice.